Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).
Han HS, Kim BJ, Jee HJ, Ryu MH, Park SH, Rha SY, Kim JG, Bae WK, Lee KW, Oh DY, Kim IH, Sym SJ, Oh SY, Kim HS, Byun JH, Kim DS, Suh YJ, An H, Zang DY.
Han HS, et al. Among authors: suh yj.
Ther Adv Med Oncol. 2021 Sep 18;13:17588359211042812. doi: 10.1177/17588359211042812. eCollection 2021.
Ther Adv Med Oncol. 2021.
PMID: 34552667
Free PMC article.